The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The impact of TP53 mutations in patients with myelofibrosis undergoing SCT
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, highlights the results of the first study that provides evidence on TP53 mutations for transplant and non-transplant settings in myelofibrosis (MF). He underscores that genotype and phenotype did not play a role in patients with or without TP53 mutations, but in TP53-mutated patients post-transplant acute myeloid leukemia (AML) was more frequent. In addition, allele frequency played an important role in overall survival (OS) and relapse-free survival (RFS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
